The SeriousTraders Newsletter If you are Serious about Trading, become a SeriousTrader!™

HeartBeam Inc. (NASDAQ: BEAT)

Investment Considerations HeartBeam has developed and secured FDA clearance for a credit card-sized 3D ECG device that enables arrhythmia assessment outside of traditional clinical settings. The company’s 12-lead ECG synthesis software successfully met pivotal study endpoints and is currently under FDA review, supporting near-term commercialization. HeartBeam’s AI algorithms, validated in collaboration with Mount Sinai, demonstrated … Continue reading “HeartBeam Inc. (NASDAQ: BEAT)”

View Profile